REGN vs. AMGN, GILD, MRNA, NTLA, VIR, VRTX, ABBV, LLY, MRK, and PFE
Should you be buying Regeneron Pharmaceuticals stock or one of its competitors? The main competitors of Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Intellia Therapeutics (NTLA), Vir Biotechnology (VIR), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), and Pfizer (PFE). These companies are all part of the "medical" sector.
Regeneron Pharmaceuticals vs. Its Competitors
Regeneron Pharmaceuticals (NASDAQ:REGN) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.
Regeneron Pharmaceuticals currently has a consensus target price of $817.67, indicating a potential upside of 46.01%. Amgen has a consensus target price of $304.43, indicating a potential upside of 10.14%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Amgen.
Regeneron Pharmaceuticals has higher earnings, but lower revenue than Amgen. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
In the previous week, Amgen had 4 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 50 mentions for Amgen and 46 mentions for Regeneron Pharmaceuticals. Amgen's average media sentiment score of 1.29 beat Regeneron Pharmaceuticals' score of 1.18 indicating that Amgen is being referred to more favorably in the news media.
83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.8% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Regeneron Pharmaceuticals pays an annual dividend of $3.52 per share and has a dividend yield of 0.6%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.4%. Regeneron Pharmaceuticals pays out 8.9% of its earnings in the form of a dividend. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Regeneron Pharmaceuticals has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.
Regeneron Pharmaceuticals has a net margin of 31.37% compared to Amgen's net margin of 18.96%. Amgen's return on equity of 174.71% beat Regeneron Pharmaceuticals' return on equity.
Summary
Regeneron Pharmaceuticals and Amgen tied by winning 10 of the 20 factors compared between the two stocks.
Get Regeneron Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Regeneron Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:REGN) was last updated on 9/12/2025 by MarketBeat.com Staff
